Literature DB >> 28632327

Photosensitivity is an early marker of neuronal ceroid lipofuscinosis type 2 disease.

Nicola Specchio1, Marcello Bellusci1,2, Nicola Pietrafusa1, Marina Trivisano1, Luca de Palma1, Federico Vigevano1.   

Abstract

OBJECTIVE: This study aimed to identify early clinical, magnetic resonance imaging (MRI), and electroencephalographic (EEG) characteristics of neuronal ceroid lipofuscinosis type 2 (CLN2) disease to enable early diagnosis, thus providing the key to early treatment, and optimized care and outcomes.
METHODS: Retrospective clinical chart review of a series of patients diagnosed with CLN2 disease from 2005 to 2015 at a single center in Italy. Clinical, MRI, and EEG findings were reviewed.
RESULTS: A total of 14 patients were included. For the whole group, median (range) age at disease onset was 3.0 (2.0-3.8) years. Epilepsy was the most commonly reported presenting symptom (in 50% [seven of 14] of patients), occurring at the age of 3.2 (2.6-3.8) years. First seizure was myoclonic in 36% (five of 14) of patients, followed by generalized tonic-clonic in 29% (4 of 14), atonic in 22% (three of 14), and focal with motor signs in 14% (two of 14). All patients walked independently at the age of 12.0 (11.0-18.0) months, but delayed speech or regression of acquired verbal skills was present in 100% of patients at 3 years. EEGs revealed a photoparoxysmal response (PPR) on intermittent photic stimulation in 93% (13 of 14) of patients. PPR was present from the first EEG, which was performed at 3.6 (3.1-4.0) years, in 43% (six of 14) of patients; it was documented at low (1-3 Hz) stimulation frequencies in 69% (nine of 13) and took the form of a flash-per-flash response in 69% (nine of 13). First brain MRI at the age of 3.8 (3.0-5.1) years revealed cerebellar atrophy in 100% (14 of 14) of patients and alteration of the periventricular white matter signal in the posterior hemispheric region in 79% (11 of 14). SIGNIFICANCE: Early photosensitivity (typically PPR at low stimulation frequencies of 1-3 Hz) is a hallmark of CLN2 disease. This diagnosis should be considered in a child presenting with any type of seizure, and particularly if it is accompanied by delayed speech and/or ataxia or MRI abnormalities (posterior white matter signal alteration or cerebellar atrophy). Wiley Periodicals, Inc.
© 2017 International League Against Epilepsy.

Entities:  

Keywords:  CLN2; Intermittent photic stimulation; Late infantile neuronal ceroid lipofuscinosis; Neuronal ceroid lipofuscinosis; Photoparoxysmal response

Mesh:

Year:  2017        PMID: 28632327     DOI: 10.1111/epi.13820

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  11 in total

Review 1.  Drug Treatment of Progressive Myoclonic Epilepsy.

Authors:  Gregory L Holmes
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

Review 2.  Recent Insight into the Genetic Basis, Clinical Features, and Diagnostic Methods for Neuronal Ceroid Lipofuscinosis.

Authors:  Konrad Kaminiów; Sylwia Kozak; Justyna Paprocka
Journal:  Int J Mol Sci       Date:  2022-05-20       Impact factor: 6.208

3.  Neuronal ceroid lipofuscinosis type 2: an Australian case series.

Authors:  Alexandra M Johnson; Simone Mandelstam; Ian Andrews; Katja Boysen; Joy Yaplito-Lee; Michael Fietz; Lakshmi Nagarajan; Victoria Rodriguez-Casero; Monique M Ryan; Nicholas Smith; Ingrid E Scheffer; Carolyn Ellaway
Journal:  J Paediatr Child Health       Date:  2020-04-24       Impact factor: 1.954

4.  Mutation update: Review of TPP1 gene variants associated with neuronal ceroid lipofuscinosis CLN2 disease.

Authors:  Emily Gardner; Mitch Bailey; Angela Schulz; Mikel Aristorena; Nicole Miller; Sara E Mole
Journal:  Hum Mutat       Date:  2019-07-26       Impact factor: 4.878

5.  Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients.

Authors:  Sara E Mole; Angela Schulz; Eben Badoe; Samuel F Berkovic; Emily C de Los Reyes; Simon Dulz; Paul Gissen; Norberto Guelbert; Charles M Lourenco; Heather L Mason; Jonathan W Mink; Noreen Murphy; Miriam Nickel; Joffre E Olaya; Maurizio Scarpa; Ingrid E Scheffer; Alessandro Simonati; Nicola Specchio; Ina Von Löbbecke; Raymond Y Wang; Ruth E Williams
Journal:  Orphanet J Rare Dis       Date:  2021-04-21       Impact factor: 4.123

Review 6.  Natural History Studies in NCL and Their Expanding Role in Drug Development: Experiences From CLN2 Disease and Relevance for Clinical Trials.

Authors:  Miriam Nickel; Angela Schulz
Journal:  Front Neurol       Date:  2022-02-08       Impact factor: 4.003

Review 7.  Neuronal Ceroid Lipofuscinosis: The Multifaceted Approach to the Clinical Issues, an Overview.

Authors:  Alessandro Simonati; Ruth E Williams
Journal:  Front Neurol       Date:  2022-03-11       Impact factor: 4.003

Review 8.  Neurophysiological Findings in Neuronal Ceroid Lipofuscinoses.

Authors:  Marina Trivisano; Alessandro Ferretti; Costanza Calabrese; Nicola Pietrafusa; Ludovica Piscitello; Giusy Carfi' Pavia; Federico Vigevano; Nicola Specchio
Journal:  Front Neurol       Date:  2022-02-25       Impact factor: 4.003

9.  Targeted re-sequencing for early diagnosis of genetic causes of childhood epilepsy: the Italian experience from the 'beyond epilepsy' project.

Authors:  Elisabetta Amadori; Marcello Scala; Giulia Sofia Cereda; Maria Stella Vari; Francesca Marchese; Veronica Di Pisa; Maria Margherita Mancardi; Thea Giacomini; Laura Siri; Fabiana Vercellino; Domenico Serino; Alessandro Orsini; Alice Bonuccelli; Irene Bagnasco; Amanda Papa; Carlo Minetti; Duccio Maria Cordelli; Pasquale Striano
Journal:  Ital J Pediatr       Date:  2020-07-06       Impact factor: 3.288

10.  An ERG and OCT study of neuronal ceroid lipofuscinosis CLN2 Battens retinopathy.

Authors:  Dorothy A Thompson; Siân E Handley; Robert H Henderson; Oliver R Marmoy; Paul Gissen
Journal:  Eye (Lond)       Date:  2021-07-16       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.